MedTrace Logo

The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study

NCT02933229 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2016-10-14

No results posted yet for this study

Summary

Helicobacter pylori (H. pylori) infection, affecting an estimated 50% of the global population, is a main cause of chronic gastritis, peptic ulcers and gastric cancer. By causing progressive damage to the stomach and may eventually result in gastric atrophy, H. pylori infection has been demonstrated to be responsible for more than 95% of gastric malignancies

Conditions

  • Helicobacter Pylori
  • the Operative Link on Gastric Intestinal Metaplasia
  • Operative Link on Gastric Intestinal Assessment

Interventions

DEVICE

biopsy

patients enrolled in the study will receive gastroscopy and biopsies in order to evaluate status of pathology.

DRUG

H. pylori eradication

H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin. If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication.

Sponsors & Collaborators

  • Shandong University

    lead OTHER

Principal Investigators

  • Li Yanqing, MD, PhD · Qilu Hospital of Shandong University

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2031-10-31
Completion
2031-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02933229 on ClinicalTrials.gov